https://pharmaphorum.com/ en Sun, 08 Jun 2025 22:35:54 +0000 Fri, 06 Jun 2025 12:34:30 +0000 https://pharmaphorum.com/news/bayer-trial-combines-two-top-drugs-kidney-disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics. Phil.Taylor https://pharmaphorum.com/news/bayer-trial-combines-two-top-drugs-kidney-disease 2025-06-06T12:34:30+0000 Feed - News and features https://pharmaphorum.com/news/digital-health-firm-omada-prices-150m-ipo In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.1 billion. Phil.Taylor https://pharmaphorum.com/news/digital-health-firm-omada-prices-150m-ipo 2025-06-06T11:30:31+0000 Feed - News and features https://pharmaphorum.com/news/az-claims-eu-approval-new-calquence-regimens-cll AstraZeneca has secured a key approval for its BTK inhibitor Calquence in Europe, currently facing a strong challenge from BeOne's rival Brukinsa. Phil.Taylor https://pharmaphorum.com/news/az-claims-eu-approval-new-calquence-regimens-cll 2025-06-06T10:21:49+0000 Feed - News and features https://pharmaphorum.com/news/wockhardt-has-high-hopes-novel-antibiotic-zaynich Wockhardt has completed a pre-filing meeting with the FDA and is preparing to submit its novel antibiotic Zaynich in the US and Europe. Phil.Taylor https://pharmaphorum.com/news/wockhardt-has-high-hopes-novel-antibiotic-zaynich 2025-06-06T08:49:05+0000 Feed - News and features https://pharmaphorum.com/news/new-auction-23andme-sought-305m-bid-ex-ceo A new auction for bankrupt genetic testing company 23andMe looks likely after former CEO Anne Wojcicki offered to outbid Regeneron. Phil.Taylor https://pharmaphorum.com/news/new-auction-23andme-sought-305m-bid-ex-ceo 2025-06-05T15:36:44+0000 Feed - News and features